Latest news
Foghorn Therapeutics Reports Q2 Results and Pipeline Progress - The Globe and MailThe Globe and Mail · Fri, 07 Aug 2026 11:46:00 GMTDiscipline and Rules-Based Execution in FHTX Response - Stock Traders DailyStock Traders Daily · Fri, 07 Aug 2026 03:36:02 GMTFoghorn Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Thu, 06 Aug 2026 14:20:38 GMTFoghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 13:50:06 GMTFoghorn Therapeutics Inc. 2026: Revenue $16.07M, EPS ($0.1) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 11:11:00 GMTLilly deal lifts Foghorn Therapeutics (Nasdaq: FHTX) Q2 2026 revenue and cuts loss - Stock TitanStock Titan · Thu, 06 Aug 2026 11:03:33 GMTFoghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update - GlobeNewswireGlobeNewswire · Thu, 06 Aug 2026 11:00:00 GMTFoghorn’s lung cancer trial advances; IND targeted for 2027 - Stock TitanStock Titan · Thu, 06 Aug 2026 11:00:00 GMT